CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Other Comprehensive Income (Loss), Net of Tax
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Other Comprehensive Income (Loss), Net of Tax of -$137.05 million for the 3-month period ending 2022-09-24, per its 10-Q filed 2022-11-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2022-11-02
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-09-24 was -$137.05M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-06-25 was -$83.62M, a 540.21% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-03-26 was -$10.19M, a 185.97% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for the quarter ending 2021-09-25 was -$24.76M, a 242.02% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for fiscal 2019 was -$5.32M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for fiscal 2018 was -$24.64M, a 122.60% decline from fiscal 2017.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for fiscal 2017 was $109.03M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other comprehensive income (loss), net of tax for fiscal 2016 was -$118.37M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2022-09-24 | -$137.05M 10-Q · filed 2022-11-02 | -$220.68M derived: sum of 2 quarters · filed 2022-11-02 | -$230.87M derived: sum of 3 quarters · filed 2022-11-02 | ||
| 2022-06-25 | -$83.62M 10-Q · filed 2022-11-02 | -$93.81M derived: sum of 2 quarters · filed 2022-11-02 | |||
| 2022-03-26 | -$10.19M 10-Q · filed 2022-11-02 | ||||
| 2021-09-25 | -$24.76M 10-Q · filed 2022-11-02 | -$5.76M derived: sum of 2 quarters · filed 2022-11-02 | $6.09M derived: sum of 3 quarters · filed 2022-11-02 | ||
| 2021-06-26 | $19.00M 10-Q · filed 2022-11-02 | $30.85M derived: sum of 2 quarters · filed 2022-11-02 | |||
| 2021-03-27 | $11.86M 10-Q · filed 2022-11-02 | ||||
| 2020-09-26 | $17.43M 10-Q · filed 2021-11-03 | $23.64M derived: sum of 2 quarters · filed 2021-11-03 | -$17.26M derived: sum of 3 quarters · filed 2021-11-03 | ||
| 2020-06-27 | $6.20M 10-Q · filed 2021-11-03 | -$34.70M derived: sum of 2 quarters · filed 2021-11-03 | |||
| 2020-03-28 | -$40.90M 10-Q · filed 2021-11-03 | ||||
| 2019-12-28 | -$5.32M 10-K · filed 2020-02-11 | ||||
| 2019-09-28 | -$12.23M 10-Q · filed 2020-10-29 | -$15.67M derived: sum of 2 quarters · filed 2020-10-29 | -$5.77M derived: sum of 3 quarters · filed 2020-10-29 | ||
| 2019-06-29 | -$3.44M 10-Q · filed 2020-10-29 | $6.47M derived: sum of 2 quarters · filed 2020-10-29 | |||
| 2019-03-30 | $9.90M 10-Q · filed 2020-10-29 | ||||
| 2018-12-29 | -$24.64M 10-K · filed 2020-02-11 | ||||
| 2018-09-29 | -$5.84M 10-Q · filed 2019-11-06 | -$34.99M derived: sum of 2 quarters · filed 2019-11-06 | -$11.39M derived: sum of 3 quarters · filed 2019-11-06 | ||
| 2018-06-30 | -$29.15M 10-Q · filed 2019-11-06 | -$5.55M derived: sum of 2 quarters · filed 2019-11-06 | |||
| 2018-03-31 | $23.60M 10-Q · filed 2019-11-06 | ||||
| 2017-12-30 | $109.03M 10-K · filed 2020-02-11 | ||||
| 2016-12-31 | -$118.37M 10-K · filed 2019-02-13 | ||||
| 2015-12-26 | -$61.47M 10-K · filed 2018-02-13 | ||||
| 2014-12-27 | -$56.47M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | -$87.93M derived: sum of 2 quarters · filed 2017-02-14 | -$75.34M derived: sum of 3 quarters · filed 2017-02-14 | -$79.62M 10-K · filed 2017-02-14 | |
| 2014-09-27 | -$31.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | -$18.88M derived: sum of 2 quarters · filed 2014-10-30 | -$23.15M 10-Q · filed 2014-10-30 | -$16.06M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-06-28 | $12.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $8.32M 10-Q · filed 2014-08-07 | $15.41M derived: sum of 3 quarters · filed 2016-02-12 | $32.86M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-03-29 | -$4.27M 10-Q · filed 2014-04-30 | $2.82M derived: sum of 2 quarters · filed 2016-02-12 | $20.27M derived: sum of 3 quarters · filed 2016-02-12 | $14.64M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2013-12-28 | $7.09M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $24.54M derived: sum of 2 quarters · filed 2016-02-12 | $18.92M derived: sum of 3 quarters · filed 2016-02-12 | -$1.18M 10-K · filed 2016-02-12 | -$817.00K 10-K · filed 2014-02-25 |
| 2013-09-28 | $17.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $11.82M derived: sum of 2 quarters · filed 2013-10-30 | -$8.28M 10-Q · filed 2013-10-30 | ||
| 2013-06-29 | -$5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | -$25.73M 10-Q · filed 2013-07-31 | |||
| 2013-03-30 | -$20.10M 10-Q · filed 2013-05-08 | ||||
| 2012-12-29 | $2.05M 10-K · filed 2015-02-17 | ||||
| 2011-12-31 | -$28.98M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |